Background: Charcot-Marie-Tooth disease (CMT) is a group of clinically and genetically heterogeneous disorders that primarily affect the peripheral nervous system. Epidemiological studies of CMT have not yet been performed in Korea. Objectives: This study was performed to estimate the prevalence of CMT in Korea and the socioeconomic status, mortality, and causes of death of Korean patients with CMT. Methods: Data on patients with CMT were obtained from the rare intractable disease registry and the National Health Insurance Service for the years 2005–2018. Results: During the study period, 2,885 CMT patients were enrolled. The prevalence per 100,000 persons in 2018 was 5.2 (6.1 for men and 4.4 for women), peaking at ages 15–39 years, with almost twice as many men (n = 714) as women (n = 402) in this age group. Of the CMT patients, 226 (7.8%) were receiving medical aid, a public assistance program targeting poor individuals, at the time of diagnosis and 253 (8.8%) at last follow-up or death. From 2005 to 2017, 170 patients died, including 118 men and 52 women. The standardized mortality ratio (SMR) was 1.57 (95% CI 1.34–1.83) for all patients and did not differ in men and women. Age-specific SMR was highest in patients aged under 9 years, gradually declining thereafter. Neurologic disease as a cause of death was significantly more frequent in CMT patients than in the general population. Conclusions: This was the first nationwide epidemiologic study of CMT patients in Korea. This study confirmed the characteristics associated with the prevalence of and mortality from CMT by age and is the first to report the socioeconomic status and causes of death of CMT patients.

Rudnik-Schöneborn S, Tölle D, Senderek J, Eggermann K, Elbracht M, Kornak U, et al. Diagnostic algorithms in Charcot-Marie-Tooth neuropathies: experiences from a German genetic laboratory on the basis of 1206 index patients.
Clin Genet
. 2016 Jan;89(1):34–43.
Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathy types I and II.
. 1980 Jun;103(2):259–80.
Barreto LC, Oliveira FS, Nunes PS, de França Costa IM, Garcez CA, Goes GM, et al. Epidemiologic study of Charcot-Marie-Tooth disease: a systematic review.
. 2016;46(3):157–65.
Kim JA, Yoon S, Kim LY, Kim DS. Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data.
J Korean Med Sci
. 2017 May;32(5):718–28.
Hong JM, Choi YC, Shin S, Lee JH, Shin HY, Kim SM, et al. Prevalence and Socioeconomic Status of Patients with Genetic Myopathy in Korea: A Nationwide, Population-Based Study.
. 2019;53(1-2):115–20.
Ahn IM, Park DH, Hann HJ, Kim KH, Kim HJ, Ahn HS. Incidence, prevalence, and survival of moyamoya disease in Korea: a nationwide, population-based study.
. 2014 Apr;45(4):1090–5.
Na KH, Kim HJ, Kim KH, Han S, Kim P, Hann HJ, et al. Prevalence, Age at Diagnosis, Mortality, and Cause of Death in Retinitis Pigmentosa in Korea-A Nationwide Population-based Study.
Am J Ophthalmol
. 2017 Apr;176:157–65.
Park SJ, Kim HJ, Park H, Hann HJ, Kim KH, Han S, et al. Incidence, prevalence, mortality and causes of death in Takayasu Arteritis in Korea - A nationwide, population-based study.
Int J Cardiol
. 2017 May;235:100–4.
SEER. World (WHO 2000–2025) standard population. 2018.
Kurihara S, Adachi Y, Wada K, Awaki E, Harada H, Nakashima K. An epidemiological genetic study of Charcot-Marie-Tooth disease in Western Japan.
. 2002 Sep-Oct;21(5):246–50.
Vaeth S, Vaeth M, Andersen H, Christensen R, Jensen UB. Charcot-Marie-Tooth disease in Denmark: a nationwide register-based study of mortality, prevalence and incidence.
BMJ Open
. 2017 Nov;7(11):e018048.
Sivera R, Sevilla T, Vílchez JJ, Martínez-Rubio D, Chumillas MJ, Vázquez JF, et al. Charcot-Marie-Tooth disease: genetic and clinical spectrum in a Spanish clinical series.
. 2013 Oct;81(18):1617–25.
Vaeth S, Christensen R, Dunø M, Lildballe DL, Thorsen K, Vissing J, et al. Genetic analysis of Charcot-Marie-Tooth disease in Denmark and the implementation of a next generation sequencing platform.
Eur J Med Genet
. 2019 Jan;62(1):1–8.
Nam SH, Hong YB, Hyun YS, Nam E, Kwak G, Hwang SH, et al. Identification of genetic causes of inherited peripheral neuropathies by targeted gene panel sequencing.
Mol Cells
. 2016 May;39(5):382–8.
Gudmundsson B, Olafsson E, Jakobsson F, Lúthvígsson P. Prevalence of symptomatic Charcot-Marie-Tooth disease in Iceland: a study of a well-defined population.
. 2010;34(1):13–7.
Yoshimura A, Yuan JH, Hashiguchi A, Ando M, Higuchi Y, Nakamura T, et al. Genetic profile and onset features of 1005 patients with Charcot-Marie-Tooth disease in Japan.
J Neurol Neurosurg Psychiatry
. 2019 Feb;90(2):195–202.
Theadom A, Roxburgh R, MacAulay E, O’Grady G, Burns J, Parmar P, et al.; Impact CMT Research Group. Prevalence of Charcot-Marie-Tooth disease across the lifespan: a population-based epidemiological study.
BMJ Open
. 2019 Jun;9(6):e029240.
Fridman V, Bundy B, Reilly MM, Pareyson D, Bacon C, Burns J, et al.; Inherited Neuropathies Consortium. CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis.
J Neurol Neurosurg Psychiatry
. 2015 Aug;86(8):873–8.
Hong YB, Park JM, Yu JS, Yoo DH, Nam DE, Park HJ, et al. Clinical characterization and genetic analysis of Korean patients with X-linked Charcot-Marie-Tooth disease type 1.
J Peripher Nerv Syst
. 2017 Sep;22(3):172–81.
Schorling E, Thiele S, Gumbert L, Krause S, Klug C, Schreiber-Katz O, et al. Cost of illness in Charcot-Marie-Tooth neuropathy: results from Germany.
. 2019 Apr;92(17):e2027–37.
Plante-Bordeneuve V, Said G. Dejerine-Sottas disease and hereditary demyelinating polyneuropathy of infancy.
Muscle Nerve
. 2002 Nov;26(5):608–21.
Sheth S, Francies K, Siskind CE, Feely SM, Lewis RA, Shy ME. Diabetes mellitus exacerbates motor and sensory impairment in CMT1A.
J Peripher Nerv Syst
. 2008 Dec;13(4):299–304.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.